Donna McEachern
- Oncology top 2%
- Peptidase Inhibition and Analysis 14
- Cancer-related Molecular Pathways 13
- Cancer Cells and Metastasis 5
- Hematology top 2%
- Multiple Myeloma Research and Treatments 12
- Molecular Biology top 2%
- Protein Degradation and Inhibitors 31
- Ubiquitin and proteasome pathways 30
- Cell death mechanisms and regulation 12
- Organic Chemistry top 2%
- Toxicology top 2%
-
- Microtubule and mitosis dynamics 5
- Cited by
- OncologyHematologyMolecular Biology
- Journals
- Journal of Medicinal Chemistry (34 papers)Cancer Research (6 papers)Molecular Cancer Therapeutics (4 papers)
- Partner nations
- United StatesChinaPoland
In The Last Decade
Donna McEachern
71 papers receiving 4.0k citations
Hit Papers
Peers
Comparison fields: 5 of 106
- Oncology 1.5k
- Hematology 557
- Molecular Biology 2.9k
- Organic Chemistry 850
- Toxicology 96
Countries citing papers authored by Donna McEachern
This map shows the geographic impact of Donna McEachern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donna McEachern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donna McEachern more than expected).
Fields of papers citing papers by Donna McEachern
This network shows the impact of papers produced by Donna McEachern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donna McEachern. The network helps show where Donna McEachern may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Donna McEachern, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 6 | |
| 3 | 2024 | 1 | |
| 4 | 2023 | 40 | |
| 5 | 2021 | 34 | |
| 6 | 2021 | 104 | |
| 7 | 2021 | 110 | |
| 8 | 2017 | 51 | |
| 9 | 2016 | 30 | |
| 10 | 2015 | 44 | |
| 11 | 2015 | 22 | |
| 12 | 2014 | 70 | |
| 13 | 2012 | 28 | |
| 14 | 2011 | 43 | |
| 15 | 2011 | 51 | |
| 16 | 2008 | 75 | |
| 17 | 2008 | 174 | |
| 18 | 1992 | 53 | |
| 19 | 1991 | 13 | |
| 20 | 1990 | 7 |
About Donna McEachern
Donna McEachern is a scholar working on Oncology, Hematology, Molecular Biology, Toxicology and Biotechnology, having authored 72 papers that have together received 4.1k indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (31 papers), Ubiquitin and proteasome pathways (30 papers), Peptidase Inhibition and Analysis (14 papers), Cancer-related Molecular Pathways (13 papers), Multiple Myeloma Research and Treatments (12 papers), Cell death mechanisms and regulation (12 papers), Microtubule and mitosis dynamics (5 papers) and Cancer Cells and Metastasis (5 papers). The work is most often cited by research in Oncology (1.5k citations), Hematology (557 citations), Molecular Biology (2.9k citations), Organic Chemistry (850 citations) and Toxicology (96 citations). Donna McEachern has collaborated with scholars based in United States, China and Poland. Frequent co-authors include Shaomeng Wang, Liu Liu, Duxin Sun, Chao‐Yie Yang, Longchuan Bai, Jianfeng Lü, Bo Wen, Yujun Zhao, Jeanne A. Stuckey and Angelo Aguilar. Their work appears in journals such as Journal of Medicinal Chemistry, Cancer Research, Molecular Cancer Therapeutics, European Journal of Cancer and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.